Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor - PubMed (original) (raw)
Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor
Shigeyuki Chaki et al. J Pharmacol Exp Ther. 2003 Feb.
Abstract
We investigated the effects of a novel melanocortin-4 (MC4) receptor antagonist,1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine (MCL0129) on anxiety and depression in various rodent models. MCL0129 inhibited [(125)I][Nle(4)-D-Phe(7)]-alpha-melanocyte-stimulating hormone (alpha-MSH) binding to MC4 receptor with a K(i) value of 7.9 nM, without showing affinity for MC1 and MC3 receptors. MCL0129 at 1 microM had no apparent affinity for other receptors, transporters, and ion channels related to anxiety and depression except for a moderate affinity for the sigma(1) receptor, serotonin transporter, and alpha(1)-adrenoceptor, which means that MCL0129 is selective for the MC4 receptor. MCL0129 attenuated the alpha-MSH-increased cAMP formation in COS-1 cells expressing the MC4 receptor, whereas MCL0129 did not affect basal cAMP levels, thereby indicating that MCL0129 acts as an antagonist at the MC4 receptor. Swim stress markedly induced anxiogenic-like effects in both the light/dark exploration task in mice and the elevated plus-maze task in rats, and MCL0129 reversed the stress-induced anxiogenic-like effects. Under nonstress conditions, MCL0129 prolonged time spent in the light area in the light/dark exploration task and suppressed marble-burying behavior. MCL0129 shortened immobility time in the forced swim test and reduced the number of escape failures in inescapable shocks in the learned helplessness test, thus indicating an antidepressant potential. In contrast, MCL0129 had negligible effects on spontaneous locomotor activity, Rotarod performance, and hexobarbital-induced anesthesia. These observations indicate that MCL0129 is a potent and selective MC4 antagonist with anxiolytic- and antidepressant-like activities in various rodent models. MC4 receptor antagonists may prove effective for treating subjects with stress-related disorders such as depression and/or anxiety.
Similar articles
- Anxiolytic-like effect of a selective and non-peptidergic melanocortin 4 receptor antagonist, MCL0129, in a social interaction test.
Shimazaki T, Chaki S. Shimazaki T, et al. Pharmacol Biochem Behav. 2005 Mar;80(3):395-400. doi: 10.1016/j.pbb.2004.11.014. Epub 2005 Jan 16. Pharmacol Biochem Behav. 2005. PMID: 15740781 - Novel piperazines: potent melanocortin-4 receptor antagonists with anxiolytic-like activity.
Nozawa D, Okubo T, Ishii T, Takamori K, Chaki S, Okuyama S, Nakazato A. Nozawa D, et al. Bioorg Med Chem. 2007 Mar 15;15(6):2375-85. doi: 10.1016/j.bmc.2007.01.019. Epub 2007 Jan 18. Bioorg Med Chem. 2007. PMID: 17267226 - Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, Kumagai T, Okubo T, Tomisawa K. Okuyama S, et al. J Pharmacol Exp Ther. 1999 May;289(2):926-35. J Pharmacol Exp Ther. 1999. PMID: 10215672 - Melanocortins and feeding behavior.
Vergoni AV, Schiöth HB, Bertolini A. Vergoni AV, et al. Biomed Pharmacother. 2000 Apr;54(3):129-34. doi: 10.1016/S0753-3322(00)89045-9. Biomed Pharmacother. 2000. PMID: 10840589 Review. - Do animal models of anxiety predict anxiolytic-like effects of antidepressants?
Borsini F, Podhorna J, Marazziti D. Borsini F, et al. Psychopharmacology (Berl). 2002 Sep;163(2):121-41. doi: 10.1007/s00213-002-1155-6. Epub 2002 Aug 8. Psychopharmacology (Berl). 2002. PMID: 12202959 Review.
Cited by
- The effect of SSRIs on unconditioned anxiety: a systematic review and meta-analysis of animal studies.
Heesbeen EJ, van Kampen T, Verdouw PM, van Lissa C, Bijlsma EY, Groenink L. Heesbeen EJ, et al. Psychopharmacology (Berl). 2024 Sep;241(9):1731-1755. doi: 10.1007/s00213-024-06645-2. Epub 2024 Jul 9. Psychopharmacology (Berl). 2024. PMID: 38980348 Free PMC article. Review. - Divergent Pharmacology and Biased Signaling of the Four Melanocortin-4 Receptor Isoforms in Rainbow Trout (Oncorhynchus mykiss).
Ji RL, Liu T, Hou ZS, Wen HS, Tao YX. Ji RL, et al. Biomolecules. 2023 Aug 16;13(8):1248. doi: 10.3390/biom13081248. Biomolecules. 2023. PMID: 37627313 Free PMC article. - The Melanocortin System: A Promising Target for the Development of New Antidepressant Drugs.
Markov DD, Dolotov OV, Grivennikov IA. Markov DD, et al. Int J Mol Sci. 2023 Apr 3;24(7):6664. doi: 10.3390/ijms24076664. Int J Mol Sci. 2023. PMID: 37047638 Free PMC article. Review. - Endogenous cannabinoids are required for MC4R-mediated control of energy homeostasis.
Yong Y, Cakir I, Lining Pan P, Biddinger JE, Bluett RJ, Mackie K, Bingham N, Patel S, Ghamari-Langroudi M. Yong Y, et al. Proc Natl Acad Sci U S A. 2021 Oct 19;118(42):e2015990118. doi: 10.1073/pnas.2015990118. Proc Natl Acad Sci U S A. 2021. PMID: 34654741 Free PMC article. - A critical inquiry into marble-burying as a preclinical screening paradigm of relevance for anxiety and obsessive-compulsive disorder: Mapping the way forward.
de Brouwer G, Fick A, Harvey BH, Wolmarans W. de Brouwer G, et al. Cogn Affect Behav Neurosci. 2019 Feb;19(1):1-39. doi: 10.3758/s13415-018-00653-4. Cogn Affect Behav Neurosci. 2019. PMID: 30361863 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical
Molecular Biology Databases